Expanding LightOx Probes capability through analytical methodologies and analysis to broaden customer base.

LightOx希望通过开发具有针对细胞亚型和细胞内细胞器的内在化学特性的新型试剂来推进使用荧光的生物成像科学领域。这一实验的基础来自于大学研究所15年的研究背景，现在由公司和其他研究机构合作进行。该项目有许多可能的结果，以及与之相关的不确定性和风险。由于我们从根本上改变了这些分子的化学结构和电子性质，因此无法保证成功。我们已经通过今年的出版物和我们专利组合的授予证明了这门科学是新颖的和未被发现的，因此，我们相信我们有一个利基领域的发展工作。通过仔细的实验设计，我们已经计划了一个过度的研究和开发，D计划跨越未来两年，这将使我们能够调查我们的新型显像剂在各种疾病状态下的关系，生物体，包括癌、哺乳动物、植物、真菌和细菌物种。迄今为止，我们已经开发了130多种成像剂，并有3个化学家族。作为这个A4i项目的一部分，我们将测试从每个家庭中选择的探针作为双光子生物显微镜的代理。这种成像技术与传统的显微镜相比有许多好处，包括使用对生物样品毒性较小的光，并且可以穿透更深。NPL和LightOx之间合作产生的数据对于在该领域开辟新市场至关重要。我们渴望与全球领先的机构合作，调查和降低我们工作的风险。只有通过这种独特的人员组合，我们才能够实现我们的目标，而且我们能够通过同行评审流程发表和申请专利的事实表明，这项工作对我们的团队来说是真正独特的。

LightOx looks to advance the scientific field of biological imaging using fluorescence by developing novel agents that have intrinsic chemical properties for targeting cell subtypes and intracellular organelles. The experimental basis of this comes from a background of 15 years of research within university institutes and are now being undertaken by the company and in collaboration with other research institutes. The project has many possible outcomes and a level of uncertainty and risk associated with it. As we are fundamentally changing the chemical structure and electronic nature of these molecules there is no guarantee of success. We have shown this science is both novel and undiscovered through the publications presented this year and the granting of our patent portfolio, and as such we believe we have a niche area of development to work within.By careful experimental design we have planned an over-arching R&D programme spanning the next two years that will allow us to investigate the relationships of our novel imaging agents in a variety of disease states and organisms including cancerous, mammalian, plant, fungal and bacterial species. We have developed over 130 imaging agents to date and have 3 chemical families. As part of this A4i project we will test selected probes from each family as agents for 2 photon biological microscopy. This imaging technique has many benefits over more conventional microscopy, including the use of light that is less toxic to biological samples and that can penetrate more deeply. The data arising from the collaboration between NPL and LightOx is essential to open new markets in this area. We are eager to partner with leading global institutes to investigate and de-risk our work. It is only with this unique mixture of people are we able to achieve our goals, and the fact we are able to publish and patent with peer review processes shows this work to be truly unique to our team.